


www.tajpharma.com

MITOCYTE® (mitomycin for injection, USP) (also known as mitomycin and/or mitomycin-C) is an antibiotic isolated from the broth of *Streptomyces caespitosus* which has been shown to have antitumor activity. The compound is heat stable, has a high melting point, and is freely soluble in organic solvents.

MITOCYTE®
Mitomycin-C kyowa powder
for solution for injection **2/10/40 (MG)**



MITOCYTE®
Mitomycin-C kyowa powder
for solution for injection **2/10/40 (MG)**

MITOCYTE® (mitomycin for injection, USP) (also known as mitomycin and/or mitomycin-C) belongs to the group of cancer-fighting medications known as antineoplastics, and specifically to the group of antineoplastics called actinomycins. Another actinomycin is dactinomycin. MITOCYTE® (also known as mitomycin and/or mitomycin-C) kills cancer cells by interfering with their growth and reproduction. It is used alone or in combination with other antineoplastic medications, radiation, or surgery to treat certain types of stomach and colon cancer. It is also used to treat a certain type of cancer of the bladder.

PHARMACOLOGICAL CLASSIFICATION:

A 26 –Cytostatic Agents

PHARMACOLOGICAL ACTION:

MITOCYTE® acts as a bifunctional or trifunctional alkylating agent. It inhibits DNA synthesis and cross-links DNA to an extent proportional to its content of guanine and cytosine. Its action is most prominent during the late G1 and early S phases of the cell cycle.

INDICATIONS: Mitomycin-C is a broad spectrum cytostatic. Used on its own Mitomycin-C may be effective in the treatment of a wide variety of malignant tumours such as breast cancer and gastro-intestinal cancer. It is, however, very often used in combination with other cytostatics particularly in the treatment of gastric and pancreatic cancers. Mitomycin-C has also been reported to have an effect in the treatment of bladder cancer, non-small cell lung cancer, head and neck squamous cell cancer, and colorectal cancer.

CONTRA-INDICATIONS:

MITOCYTE® should not be used in patients suffering from an active infection.

MITOCYTE® is contra-indicated in pregnancy. Safety during lactation has not been established. Patients with a history of hypersensitivity to MITOCYTE®. Use with caution in patients with hepatic disorder, renal disorder, bone marrow suppression or in patients with varicella (fatal systemic disorders may occur). Administration to children and reproductive patients should be carried out considering its potential effects to the gonads.

Individual vials each containing 2 mg /10 mg or 40 mg.

Food and Drug Administration (FDA) approved .Prescription Only (POM)

A Taj Pharma"India Product